文献速递甲状腺与颈部外科围术期管理与 ERAS

Lugol液在Graves病全甲状腺切除术前作用的随机临床试验

Role of Lugol solution before total thyroidectomy for Graves' disease: randomized clinical trial.
PubMed 文献 · Br J Surg · 2024-01-01

结果显示Lugol液显著降低FT3和FT4水平,但未减少术中/术后失血、甲状腺血管化、手术时间或术后并发症。

要点

  • 术前Lugol液可显著降低Graves病患者FT3和FT4水平。
  • Lugol液未减少术中/术后失血(中位数80.5 vs 94 ml)。
  • Lugol液未缩短手术时间(两组均75分钟)或降低术后并发症。

核心结论

  • Lugol液显著降低Graves病手术患者的FT3和FT4水平,但不减少术中/术后失血、甲状腺血管化、手术时间或术后并发症。

主要发现

  • Lugol液组术后当天FT3和FT4水平较术前第8天显著降低,未用Lugol液组无此变化。
  • 两组术前至术日超声血管化评估无差异,组织学微血管密度也无差异。
  • Lugol液组与未用Lugol液组术中/术后失血中位数分别为80.5 ml和94 ml,无显著差异。
  • 两组手术时间均为75分钟,术后并发症无显著差异。

临床怎么用

  • Lugol液可用于降低Graves病患者术前甲状腺激素水平,但不应期望其减少术中失血或血管化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lugol solution is often administered to patients with Graves' disease before surgery. The aim is to reduce thyroid vascularization and surgical morbidity, but its real effectiveness remains controversial. The present study was designed to evaluate the effects of preoperative Lugol solution on thyroid vascularization and surgical morbidity in patients with Graves' disease undergoing total thyroidectomy. METHODS: Fifty-six patients undergoing total thyroidectomy for Graves' disease were randomly assigned to receive 7 days of Lugol treatment (Lugol+ group, 29) or no Lugol treatment (LS- group, 27) before surgery in this single-centre and single-blinded trial. Preoperative hormone and colour Doppler ultrasonographic data for assessing thyroid vascularization were collected 8 days before surgery (T0) and on the day of surgery (T1). The primary outcome was intraoperative and postoperative blood loss. Secondary outcomes included duration of surgery, thyroid function, morbidity, vascularization, and microvessel density at final pathology. RESULTS: No differences in demographic, preoperative hormone or ultrasonographic data were found between LS+ and LS- groups at T0. At T1, free tri-iodothyronine (FT3) and free thyroxine (FT4) levels were significantly reduced compared with T0 values in the LS+ group, whereas no such variation was observed in the LS- group. No differences between T0 and T1 were found for ultrasonographic vascularization in either group, nor did the histological findings differ. There were no significant differences between the LS+ and LS- groups concerning intraoperative/postoperative blood loss (median 80.5 versus 94 ml respectively), duration of surgery (75 min in both groups) or postoperative morbidity. CONCLUSION: Lugol solution significantly reduces FT3 and FT4 levels in patients undergoing surgery for Graves' disease, but does not decrease intraoperative/postoperative blood loss, thyroid vascularization, duration of surgery or postoperative morbidity. REGISTRATION NUMBER: NCT05784792 (https://www.clinicaltrials.gov).

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Schiavone D, Crimì F, Cabrelle G, et al. Role of Lugol solution before total thyroidectomy for Graves' disease: randomized clinical trial. Br J Surg. 2024. PMID: 39129619. doi:10.1093/bjs/znae196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。